Clinical Trial Update: A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 randomized, open-label study evaluating ASC09F with ritonavir for 2019-nCoV pneumonia (COVID-19).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• 2019-ncov Pneumonia

Drugs mentioned

• ASC09F
• Ritonavir (Ritonavir)

Snippet

Sponsor: Tongji Hospital | Conditions: 2019-nCoV Pneumonia | Phase 3 | Status: UNKNOWN